imatinib mesylate has been researched along with Afibrinogenemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cortelezzi, A; Fracchiolla, NS; Sciumè, M | 1 |
| Chauhan, R; Harankhedkar, S; Mahapatra, M; Nair, RR; Saxena, R | 1 |
2 other study(ies) available for imatinib mesylate and Afibrinogenemia
| Article | Year |
|---|---|
Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Afibrinogenemia; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinogen; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2018 |
Imatinib-induced platelet dysfunction and hypofibrinogenemia in chronic myeloid leukemia.
Topics: Afibrinogenemia; Blood Platelet Disorders; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines | 2019 |